Robert Burrows Email & Phone Number

Professional investor relations executive with demonstrated success in developing and leading multifaceted and comprehensive IR strategies for public companies – for the last 23 years principally healthcare companies focused on vaccines, therapeutics, bi-specific antibodies, antimicrobials, biodefense medical countermeasures, medical devices, drug/device combinations, plasma-derived immunoglobulins, immune-oncology antibody protein therapeutics, biologics manufacturing, plasma fractionation, contract manufacturing (development services/drug substance/drug product) services, and other related areas. Disease areas of focus have included: infectious diseases (anthrax, botulism, smallpox, typhoid, cholera, COVID-19, dengue, tuberculosis, pandemic influenza, Ebola, Men-B, Hep-B, GBS, and chlamydia), chemical weapon agents and toxic industrial chemical threats, nerve agent threats, traveler’s diseases (typhoid, cholera, and chikungunya) and threats related to the opioid epidemic (opioid overdose reversal; opioid use disorder (OUD)).Strategic thinker, successful cross-functional team member, and skillful problem solver.Adept and agile communicator, consensus builder, motivator, and change agent with extensive leadership experience in building relationships among senior management, mid-level management, board members, sellside analysts, buyside analysts, buyside portfolio managers, investment bankers, credit and treasury representatives, and other strategic stakeholders.High comfort level working in complex, ambiguous and rapidly changing environments.Experience with multiple IR-related matters, including: initial public offering, follow-on equity capital raise, issuance of convertible note, issuance of rated debt, amendment and extension of maturity of senior secured debt, share repurchase, “at-the-market” (ATM) equity program, asset/division/whole-company acquisition, corporate strategy development and dissemination, asset sale/divisional spin-out, manufacturing site visit, business divestiture, receipt of and response to FDA Warning Letter, shareholder activism, founder transition, CEO transition and multiple rounds of employee reductions-in-force (RIF).

Listed skills include Strategy, Investor Relations, Biotechnology, Cross Functional Team Leadership, and 18 others.